Weight-loss injections vs tablets
The real choice is not simply needle or tablet. Weekly injections and oral weight-loss medicines work in different ways, raise different suitability questions and can have very different price and support patterns.
Different formats, different questions
If you are comparing effectiveness
Do not compare by format alone. Mounjaro, Wegovy, Orlistat, Xenical and Mysimba are different medicines, and personal response is not guaranteed by headline averages.
If you are comparing convenience
Weekly injections may sound simpler, but dose changes, storage, delivery and follow-up still matter. Tablets and capsules may be easier to start, but daily or meal-linked use can be less convenient for some people.
If you are comparing cost
Oral options often have lower starting prices, while injections usually carry a higher monthly cost. The fair comparison includes dose, pack size, delivery, repeat checks and support.
Start with what would change your decision
If the choice feels confusing, compare the practical trade-offs first. The right page to open next depends on whether your main question is effectiveness, ease of use, cost, checks or ongoing support.
- Effectiveness: compare individual medicines, not just injections against tablets.
- Cost: compare the ongoing monthly picture, not just a first visible price.
- Convenience: compare weekly use, daily use, meal-linked use and delivery needs.
- Support: compare how providers explain reviews, side effects, restarts and follow-up.
Injections usually revolve around dose steps and follow-up
Mounjaro and Wegovy are usually taken once a week. The practical questions are often about dose progression, side effects, review timing, supply, delivery and what happens if treatment is paused.
A provider should make the assessment process clear before treatment starts and explain how ongoing reviews work if the medicine is suitable.
Tablets and capsules are not all the same
Orlistat and Xenical contain the same active ingredient and are linked to meals. Mysimba is a different tablet treatment with different assessment questions. That means tablets should not be treated as one single option.
When comparing oral treatments, check the active ingredient, branded or generic wording, pack size, how the medicine is taken and the provider checks around it.
Injections vs tablets: practical comparison
This table compares the practical differences that usually matter before moving into individual treatment pages or provider prices.
| Compare | Weekly injections | Tablets and capsules |
|---|---|---|
| What you are comparing | Weekly injections such as Mounjaro and Wegovy. | Oral medicines such as Orlistat, Xenical and Mysimba. |
| How treatment is usually used | Usually once a week, with dose changes over time if treatment remains suitable. | Usually taken as tablets or capsules. Orlistat and Xenical are linked to meals; Mysimba follows a tablet dose schedule. |
| What the medicine is doing | Mounjaro and Wegovy work on appetite and fullness pathways. They are different medicines, so they should not be treated as interchangeable. | Orlistat and Xenical reduce fat absorption from meals. Mysimba works differently again, so the tablet group is not one single type of medicine. |
| Provider checks to expect | BMI, medical history, current medicines, previous treatment, side effects, dose history and whether ongoing review is appropriate. | BMI, medical history, current medicines, medicine interactions, diet context and whether the chosen oral option is suitable. |
| Price pattern | Often higher monthly prices. Dose, delivery, review support and supply length can change the real cost. | Often lower headline prices. Pack size, branded/generic wording, delivery and repeat supply still matter. |
| Where service detail matters | Dose availability, follow-up support, maintenance wording, restart checks and delivery handling. | Pack strength, meal-time instructions, repeat checks, delivery terms and support if side effects occur. |
A lower visible price may not mean the same service
Price can be shown in different ways: by dose, pack, first month, repeat supply or total known cost. Provider checks, delivery, support and review timing can also change the decision.
Current comparison snapshot
These figures show the reviewed treatment pages and price ranges behind this comparison. They are a snapshot, not a guarantee of availability or suitability.
| Treatment type | Medicines compared | Reviewed price range | Reviewed dates | Open hub |
|---|---|---|---|---|
| Weekly injections | Mounjaro, Wegovy | £53.94 to £359 across 390 Mounjaro prices and 326 Wegovy prices | 6 May 2026 to 24 May 2026 | Compare injections |
| Tablets and capsules | Orlistat, Xenical, Mysimba | £17.39 to £115 across 23 Orlistat prices, 15 Xenical prices and 11 Mysimba prices | 25 April 2026 to 22 May 2026 | Compare tablets |
Compare the medicines behind each format
Mounjaro
65 providers reviewed- 390 reviewed prices
- 6 May 2026 to 21 May 2026
Wegovy
66 providers reviewed- 326 reviewed prices
- 6 May 2026 to 24 May 2026
Orlistat
15 providers reviewed- 23 reviewed prices
- 25 April 2026 to 21 May 2026
Xenical
9 providers reviewed- 15 reviewed prices
- 25 April 2026 to 22 May 2026
Mysimba
7 providers reviewed- 11 reviewed prices
- 25 April 2026 to 22 May 2026
Do not assume every GLP-1 tablet is a UK weight-loss option
Interest in tablet-based GLP-1 options is growing, but current UK comparison pages should separate licensed weight-loss treatments from medicines used for other conditions or options that are still emerging.
If you are comparing what is available now, use the current injection and oral-treatment pages, then confirm suitability with a regulated provider.
Useful comparisons from here
Mounjaro vs Wegovy
Compare the two weekly injection options side by side.
Orlistat vs Mysimba
Compare two oral treatment options with different active ingredients.
Provider directory
Check provider pages for visible prices, checks, delivery and support details.
Comparison next step
Take the comparison into live route and provider context
The strongest next step is usually the provider shortlist, the treatment pages for each brand, and the main semaglutide guide rather than stopping at one verdict line.
Source checks
Mysimba Prescribing Information
The Mysimba Summary of Product Characteristics was reviewed for medicine identity and prescribing-information context.
Checked: 27 April 2026 Confidence: High
Source: eMC: Mysimba 8 mg/90 mg prolonged-release tablets SmPC
Reviewed for tablet-route identity context where Mysimba is named as one of the examples.
Orlistat Tablet Context
NHS medicines information was reviewed for orlistat background.
Checked: 27 April 2026 Confidence: High
Source: NHS medicines: Orlistat
Used to support public explanation of tablet differences and why pack-aware comparison matters.
Glp1 Safety And Prescription Context
GOV.UK/MHRA patient information was reviewed for GLP-1 medicine safety and prescription-only context.
Checked: 27 April 2026 Confidence: High
Source: GOV.UK: GLP-1 medicines for weight loss and diabetes
Reviewed for cautious wording around regulated supply, assessment and side-effect support on injection routes.
NHS Obesity Treatment Context
NHS guidance was reviewed for broad obesity treatment pathway context.
Checked: 27 April 2026 Confidence: High
Source: NHS: Treatment for obesity
Reviewed to explain that treatment pathways can differ and should not be reduced to a simple price comparison.
NICE Weight Management Guidance
NICE guidance was reviewed for broad UK overweight and obesity management context.
Checked: 27 April 2026 Confidence: High
Source: NICE NG246: Overweight and obesity management
Reviewed for cautious general guidance language rather than medicine-specific recommendations.
Important information
This website is an informational comparison hub. It does not prescribe, supply or sell prescription-only medicines. Suitability depends on a regulated clinical assessment.
Some links may be affiliate or commercial links. Commercial relationships must not change the way safety, eligibility, source checks or editorial context are presented.